Gilead Sciences | GILD - Ebit


Gilead Sciences reported $2.68B in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 502.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 344.17M 39.71M Mar/2026
J&J USD 6.62B 1.51B Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.18B 118M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sanofi EUR 1.94B 239M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026